An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma
Status:
Recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
Radiotherapy is a regular care for metastatic solid tumors or lymphoma, and it can induce
immunogenic death of tumor cells and a stronger immune response. Sometimes, tumor regression
would be observed at sites distant to an irradiated field because of the radiotherapy-induced
anticancer immune responses, so-called abscopal response. Manganese has been confirmed to
activate innate immune and function as anticancer immunoadjuvant in pre-clinical studies.
This study is designed to assess the abscopal response and safety of combined therapy of
manganese and radiotherapy in patients with metastatic solid tumors or lymphoma.